Shares of Regeneron Pharmaceuticals REGN surged higher on Monday as speculation grew that the FDA will authorize its coronavirus treatment for emergency use.REGN closed up over 7% to $605.08 per share. The pharma stock has gained about 23% over the past six monthsRegeneron’s treatment was given to President Trump over the weekend after he was taken to Walter Reed Medical Center following his Covid-19 diagnosis. Trump’s doctors said he received an infusion of the company’s dual antibody treatment.The drug is known as REGN-COV2, and is currently being evaluated in a trial that is studying its use in early coronavirus infections.5 Stocks Set to DoubleEach was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research